The Profile of Interleukin-6, PGE2, and Menstrual Pain Levels through the Counter-Pressure Regiosacralis Therapy
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 6, Pages 122-128
AbstractMenstrual pain (dysmenorrhea) is a pain frequently felt by most women due to the progesterone hormone instability in blood. The pain is commonly felt since the first day of the menstrual period. The mostly used therapy for dysmenorrhea was the pain killing therapy which resulted to a number of bad side effects such as organ damage and hypertension. The non-pharmacological therapies, such as the counter-pressure region sacralis may become an effective and safe alternative to reduce pain. This research aims at describing the profile of interleukin-6, PGE2, and menstrual pain levels through counter-pressure region sacralis therapy. A quasiexperimental research method was conducted with research samples of 50 female teenagers who meet the inclusion criteria. Counter-pressure interventions were given three times when the pain occurred for 45-50 second per treatment. The pain level was measured before and after treatment through Numeric Rating Scale. The research result showed that respondents’ average age was 18.74 (± 3.148) years old, with the youngest age of 15 years old, and the oldest age of 35 years old; most respondents had their first menstrual period (menarche) at the age of 12.58 (± 1.23) years old; the average pain scale before intervention was 5.0 (± 1.54;max 3;min 9); the average pain scale after intervention was 2.53 (± 1.474;max 7;min 1); the average Interleukin-6 was 4.82 (± 5.66) pg/ml; and the average prostaglandin E-2 was 994.73 (± 221.82) pg/ml. This research concludes that counter-pressure region sacralis is effective to decrease menstrual pain.
- Article View: 186
- PDF Download: 180